Compare Novavax Inc (NVAX) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Plby Group Inc — how do they compare? Novavax Inc trades at $9.86 (market cap $1.62B), while Plby Group Inc trades at $1.16 (market cap $138.38M). The key difference: Novavax Inc is far larger — about 11.7× Plby Group Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | PLBY | |
|---|---|---|
Market Cap | $1.62B | $138.38M |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $2.71 |
52-Week Low | $6.22 | $1.11 |
Enterprise Value | $1.20B | $283.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
PLBY trades at $1.18, up 0.85% with a bearish technical signal despite positive cash flow trends. The company shows improving fundamentals with revenue stabilizing around $120M and net losses narrowing significantly from -$278M in 2022 to -$13M in 2025. Recent Q2 2026 earnings beat expectations with a return to operating profitability, while analyst consensus remains strongly bullish with 75% buy ratings.
The outlook suggests cautious optimism as PLBY demonstrates operational turnaround with five consecutive quarters of positive EBITDA. Key risks include high debt levels and negative shareholder equity, but recent share repurchases and Russell index inclusion provide support. The stock faces resistance near current levels with technical indicators signaling caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
